Company Overview
- Website
- morphosys.com
- Phone
- (617) 714-0555
- Employees
- 61
- Founded in
- 2008
- Industry
- Materials/Manufacturing
- NAICS Codes
-
54 - Professional, Scientific, and Technical Services541 - Professional, Scientific, and Technical Services5413 - Architectural, Engineering, and Related Services54138 - Testing Laboratories and Services
- SIC Codes
-
28 - Chemicals and Allied Products283 - Drugs2834 - Pharmaceutical Preparations80 - Health Services
Financials & Stats
Revenue
$27B
Total Funding Amount
$708M
Recent News & Media
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
- Nov 18, 2024
- pmc.ncbi.nlm.nih.gov
EX-99.2
- Aug 6, 2024
- sec.gov
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company - Case - Faculty & Research
- Oct 5, 2023
- hbs.edu
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
- Jun 11, 2021
- globenewswire.com
MorphoSys to Acquire Constellation Pharmaceuticals
- Jun 8, 2021
- willkie.com
MorphoSys to acquire Constellation Pharmaceuticals for $1.7bn
- Jun 3, 2021
- pharmaceutical-technology.com
Who is Constellation Pharmaceuticals
Constellation Pharmaceuticals is a company based in Boston, Massachusetts. It has 61 employees and generated $27 million in revenue. MorphoSys acquired Constellation Pharmaceuticals in July 2021. MorphoSys is a global commercial-stage biopharmaceutical company focused on developing innovative cancer medicines. MorphoSys uses groundbreaking science and technologies to discover, develop, and deliver these medicines to patients. For more information, visit www.morphosys.com.